

10/560281

IAP13 RGC/PCT/PTO 12 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: TACHIBANA1

In re Application of:)	Conf. No.:
Kazutaka TACHIBANA et al.)	
)	
IA No: PCT/JP2004/008211)	Art Unit:
)	
IA Filed: June 11, 2004)	Examiner:
)	
Appln. No.:)	Washington, D.C.
Not yet assigned)	
)	December 12, 2005
For: IMIDAZOLIDINE DERIVATIVE)	
)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[] B. before the mailing date of a first office action on the merits or before the mailing of a first Office

action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

[X] A. Document AE is deemed substantially cumulative to documents AJ, and, in accordance with 37 CFR §1.98(c), a copy of each of the former document(s) is not enclosed.

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

[X] 3. Documents AE-AI are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of documents AH-AI (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[X] For documents AE-AI, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with

a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.

[X] A concise explanation of the relevance of documents AD-AI are found in the attached INTERNATIONAL search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] A concise explanation of the relevance of documents _____ is set forth as follows:

[X] A concise explanation of the relevance of documents AE-AF can be found on pages 2-4 of the specification.

[] A concise explanation of the relevance of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] 5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the


IAP13 RECEIVED TO 13 DEC 2005

face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicants

By:


Roger L. Browdy
Registration No. 25,618

RLB:ccw
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\Y\YUAS\Tachibana1\pto\ids.fee.doc

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number Not yet assigned
 Filing Date December 12, 2005
 First Named Inventor Kazutaka TACHIBANA
 Group Art Unit _____
 Examiner Name _____
 Attorney Docket Number TACHIBANA1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5411981	05/02/1995	GAILLARD-KELLY et al.	
	AB	US-5627201	05/06/1997	GAILLARD-KELLY et al.	
	AC	US-35,956	11/10/1998	GAILLARD-KELLY et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AD	GB 2118942 A1	04/27/1982	CIBA-GEIGY AG		
	AE	JP 02-528434 S	09/03/2002	DOMPE' S.P.A.		
	AF	JP 10-510845 A	10/20/1998	BIOPHYSICA FOUNDATION		
	AG	JP 4-308579 A	10/30/1992	ROUSSEL UCLAF		
	AH	JP 58-194891 A	11/12/1983	CIBA-Geigy AG		
	AI	JP 6-73017 A	03/15/1994	ROUSSEL UCLAF		
	AJ	WO 00/24710	05/04/2000	DOMPE' S.P.A.		
	AK	WO 97/00071	01/03/1997	BIOPHYSICA FOUNDATION		
	AL	EP 580459 A1	01/26/1994	ROUSSEL-UCLAF		
	AM	EP 0494819 A1	07/15/1992	ROUSSEL-UCLAF		
	AN	WO 03/093243 A1	11/13/2003	AVENTIS PHARMA DEUTSCHLAND GMBH		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AO	WONG, Choi-iok, "Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide", vol. 270, no. 34, pp. 19998-20003, 1995	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.